Juan F. Gallegos-Orozco
( out of 74 reviews )

Juan F. Gallegos-Orozco, MD

Languages spoken: Spanish, English

Clinical Locations

Primary Location

Kidney & Liver Clinic

Kidney and Liver Clinic
50 N Medical Dr
Salt Lake City , UT 84132
801-213-9797
Get Directions

Boise Area Specialty Clinic

3875 East Overland Road
Meridian , ID 83642
Get Directions

Redwood Health Center

General Endoscopy
1525 West 2100 South
Salt Lake City , UT 84119
801-213-9797
Get Directions
Show 2 more location(s)

Sugar House Health Center

1280 E. Stringham Avenue
Salt Lake City , UT 84106
801-581-2000
Get Directions

University of Utah Hospital

Liver Transplant
50 N Medical Dr
Salt Lake City , UT 84132
801-213-9797
Get Directions

  • Dr. Juan F. Gallegos-Orozco graduated from medical school in Mexico and completed post-graduate medical education in Internal Medicine and Gastroenterology in both Mexico and the United States, where he completed fellowship training in Transplant Hepatology at the prestigious Mayo School of Graduate Medical Education, Mayo Clinic in Phoenix, Arizona in June 2012. His main clinical and research interests include the management of chronic viral hepatitis, non-alcoholic fatty liver disease and liver transplantation. He has published many research articles on these and other topics and has authored several book chapters pertaining to liver diseases. Dr. Gallegos-Orozco joined the Division of Gastroenterology, Hepatology and Nutrition at the University of Utah School of Medicine in July, 2012 and is currently an Associate Professor of Medicine and serves as the Medical Director for Hepatology and Liver Transplant.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Gastroenterology)
    Mexican Board of Internal Medicine
    Mexican Board of Gastroenterology
    Mexican Board of Gastroenterology (Sub: Gastrointestinal Endoscopy)
    American Board of Internal Medicine (Sub: Transplant Hepatology)

    Patient Rating

    4.9 /5
    ( out of 74 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    UH HOSPITALS AND CLINICS

    Dr. Gallegos-Orozco in my opinion is one of the best liver doctors in the country I am glad he is here in University of Utah hospital.

    UH HOSPITALS AND CLINICS

    He is amazing!

    UNIVERSITY HOSPITAL

    Thank you Dr.Gallegos for being such a great dr I appreciate everything you do.

    UH HOSPITALS AND CLINICS

    Dr. Gallegos is smart and straight forward. He is skilled and it is obvious in his care, team respect and my struggle to recover from a devastating illness, liver failure. Thank you

    UH HOSPITALS AND CLINICS

    Outstanding physician

    UH HOSPITALS AND CLINICS

    Dr. Gallegos has always been courteous, caring and professional. Most importantly, I have confidence that he is knowledgeable in treating my chronic condition.

    UH HOSPITALS AND CLINICS

    I would be proud to tell everyone what a great and caring Dr he is. Thank you for always listening to me. Thank you for saving my life.

    UH HOSPITALS AND CLINICS

    I feel that he has taken interest in my health care.

    UH HOSPITALS AND CLINICS

    Dr. Gallegos is an excellent provider.He shows concern, interest and empathy for the patient.It's a privilege to have him as my liver doctor.

  • Dr. Juan F. Gallegos-Orozco graduated from medical school in Mexico and completed post-graduate medical education in Internal Medicine and Gastroenterology in both Mexico and the United States, where he completed fellowship training in Transplant Hepatology at the prestigious Mayo School of Graduate Medical Education, Mayo Clinic in Phoenix, Arizona in June 2012. His main clinical and research interests include the management of chronic viral hepatitis, non-alcoholic fatty liver disease and liver transplantation. He has published many research articles on these and other topics and has authored several book chapters pertaining to liver diseases. Dr. Gallegos-Orozco joined the Division of Gastroenterology, Hepatology and Nutrition at the University of Utah School of Medicine in July, 2012 and is currently an Associate Professor of Medicine and serves as the Medical Director for Hepatology and Liver Transplant.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor (Clinical)
    Academic Divisions Gastroenterology
    Board Certification
    American Board of Internal Medicine (Sub: Gastroenterology)
    Mexican Board of Internal Medicine
    Mexican Board of Gastroenterology
    Mexican Board of Gastroenterology (Sub: Gastrointestinal Endoscopy)
    American Board of Internal Medicine (Sub: Transplant Hepatology)

    Education history

    Professional Medical Medicine with Honors, (Suma cum Laude equivalent) - Universidad Nacional Autónoma de México M.D.
    Clerkship Cardiology - University of New Mexico Hospital, University of New Mexico Medical School Clinical Clerkship
    Clerkship Gastroenterology - University of New Mexico Hospital, University of New Mexico Medical School Clinical Clerkship
    Residency Internal Medicine - Universidad Nacional Autónoma de México Resident
    Fellowship Gastroenterology - Universidad Nacional Autónoma de México Fellow
    Residency Internal Medicine - Mayo Clinic College of Medicine Resident
    Fellowship Gastroenterology - Mayo Clinic College of Medicine, Mayo Clinic in Arizona Fellow
    Fellowship Transplant Hepatology - Mayo Clinic College of Medicine, Mayo Clinic in Arizona Fellow

    Selected Publications

    Journal Article

    1. Bajaj JS, Brenner DM, Cai Q, Cash BD, Crowell M, DiBaise J, Gallegos-Orozco JF, Gardner TB, Gyawali CP, Ha C, Holtmann G, Jamil LH, Kaplan GG, Karsan HA, Kinoshita Y, Lebwohl B, Leontiadis GI, Lichtenstein GR, Longstreth GF, Muthusamy VR, Oxentenko AS, Pimentel M, Pisegna JR, Rubenstein JH, Russo MW, Saini SD, Samadder NJ, Shaukat A, Simren M, Stevens T, Valdovinos M, Vargas H, Spiegel B, Lacy B (2020). Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology. The American journal of gastroenterology, 115(7), 1007-1018. (Read full publication)
    2. Gallegos-Orozco JF, Silva AC, Batheja MJ, Chang YH, Hansen KL, Lam-Himlin D, De Petris G, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan DC, Silva AM, Rakela J, Vargas H (2015). Magnetic resonance elastography can discriminate normal vs. abnormal liver biopsy in candidates for live liver donation. Abdominal imaging, 40(4), 795-802. (Read full publication)
    3. Murad MH, Fernández-Balsells MM, Barwise A, Gallegos-Orozco JF, Paul A, Lane MA, Lampropulos JF, Natividad I, Perestelo-Pérez L, Ponce de León-Lovatón PG, Albuquerque FN, Carey J, Erwin PJ, Montori V (2010). Outcomes of surgical treatment for nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Clinical endocrinology, 73(6), 777-91. (Read full publication)
    4. Samadder NJ, Smith KR, Wong J, Hanson H, Boucher K, Burt RW, Charlton M, Byrne KR, Gallegos-Orozco JF, Koptiuch C, Curtin (2016). Familial Risk of Biliary Tract Cancers: A Population-Based Study in Utah. Digestive diseases and sciences, 61(12), 3627-3632. (Read full publication)
    5. Garcia-Tsao G, Fuchs M, Shiffman M, Borg BB, Pyrsopoulos N, Shetty K, Gallegos-Orozco JF, Reddy KR, Feyssa E, Chan JL, Yamashita M, Robinson JM, Spada AP, Hagerty DT, Bosch (2019). Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. Hepatology (Baltimore, Md.), 69(2), 717-728. (Read full publication)
    6. Charlton M, Levitsky J, Aqel B, O'Grady J, Hemibach J, Rinella M, Fung J, Ghabril M, Thomason R, Burra P, Little EC, Berenguer M, Shaked A, Trotter J, Roberts J, Rodriguez-Davalos M, Rela M, Pomfret E, Heyrend C, Gallegos-Orozco J, Saliba (2018). International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation, 102(5), 727-743. (Read full publication)
    7. Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G, Williams JW, Rakela J, Vargas H (2009). Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver transplantation, 15(12), 1872-81. (Read full publication)
    8. Wong YJ, Qiu TY, Tam YC, Mohan BP, Gallegos-Orozco JF, Adler D (2020). Efficacy and Safety of IV albumin for non-spontaneous bacterial peritonitis infection among patients with cirrhosis: A systematic review and meta-analysis. Digestive and liver disease, 52(10), 1137-1142. (Read full publication)
    9. Gallegos-Orozco JF, Charlton M (2017). Predictors of Cardiovascular Events After Liver Transplantation. Clinics in liver disease, 21(2), 367-379. (Read full publication)
    10. Porres-Aguilar M, Gallegos-Orozco J (2014). Hepatopulmonary syndrome: Is it time to redefine the MELD exception score for better organ allocation and outcomes?. Annals of hepatology, 13(4), 468-70. (Read full publication)
    11. Gallegos-Orozco JF, Kim R, Thiesset HF, Hatch J, Lynch K, Chaly T Jr, Shihab F, Ahmed F, Hall I, Campsen (2016). Early Results of Pilot Study Using Hepatitis C Virus (HCV) Positive Kidneys to Transplant HCV Infected Patients with End-Stage Renal Disease Allowing for Successful Interferon-Free Direct Acting Antiviral Therapy after Transplantation. Cureus, 8(11), e890. (Read full publication)
    12. Rofaiel G, Martinez E, Pan G, Sossenheimer M, O'Hara R, Gallegos J, Box T, Pham T, Campsen J, Goodale M, Kim (2019). Creation of a Robotically Assisted Terminal Jejunogastrostomy Is Safe and Effective in Regaining Antegrade Enteral Bile Duct Access After Live Donor Liver Transplant With Roux Limb. Transplantation direct, 5(8), e476. (Read full publication)
    13. Izzy M, Fortune BE, Serper M, Bhave N, deLemos A, Gallegos-Orozco JF, Guerrero-Miranda C, Hall S, Harinstein ME, Karas MG, Kriss M, Lim N, Palardy M, Sawinski D, Schonfeld E, Seetharam A, Sharma P, Tallaj J, Dadhania DM, VanWagoner L (2022). Management of Cardiac Diseases in Liver Transplant Recipients: Comprehensive Review and Multidisciplinary Practice-Based Recommendations. PMID: 35359027. American Journal of Transplant,
    14. Mohan BP, Iriana S, Khan SR, Yarra P, Ponnada S, Gallegos-Orozco JF (2022). Outcomes of liver transplantation in patients 70 years or older: a systematic review and meta-analysis. Annals of Hepatology,
    15. Mohan BP, Iriana S, Khan SR, Yarra P, Ponnada S, Gallegos-Orozco J (2022). Outcomes of liver transplantation in patients 70 years or older: a systematic review and meta-analysis. Annals of hepatology, 27(6), 100741. (Read full publication)
    16. Gallegos-Orozco JF, O'Leary JG, Reddy KG, Bindra J, Chopra I, Niewoehner J, Huang (2025). Early Diagnosis and Timely Terlipressin in Hepatorenal Syndrome Improves Projected Outcomes and Lowers Cost. ClinicoEconomics and outcomes research, 17, 615-625. (Read full publication)
    17. Trauner M, Levy C, Tanaka A, Goodman Z, Thorburn D, Joshi D, Salminen K, Yimam K, Isayama H, Montano-Loza AJ, Caldwell S, Danta M, Farkkila M, Gallegos-Orozco JF, Gordon SC, Hinrichsen H, Invernizzi P, Vuppalanchi R, Zhu K, Xu J, Liu X, Lu X, Crans G, Bolbolan S, Boyette L, Alani M, Barchuk WT, Watkins TR, Genovese MC, Bowlus C (2025). Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial. The lancet. Gastroenterology & hepatology, (Read full publication)
    18. Boike JR, Gallegos-Orozco JF, Duarte-Rojo (2025). Rallentando un Poco : Carvedilol and Its Role in Cirrhosis Progression. The American journal of gastroenterology, (Read full publication)
    19. Jensen MK, Gallegos-Orozco J (2025). Less salt and more water for children-not just dietary, but transplant management too. Liver transplantation, 31(5), 569-570. (Read full publication)

    Review

    1. Gallegos-Orozco JF, Foxx-Orenstein AE, Sterler SM, Stoa J (2012). Chronic constipation in the elderly. The American journal of gastroenterology, 107(1), 18-25; quiz 26. (Read full publication)
    2. Unzueta A, Gallegos-Orozco J (2013). Noninvasive diagnosis of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Oncology Gastroenterology Hepatology Reports. Oncology, 2, 8-16.
    3. Porres-Aguilar M, Gallegos-Orozco JF, Garcia H, Aguirre J, Macias-Rodriguez RU, Torre-Delgadillo (2013). Pulmonary vascular complications in portal hypertension and liver disease: a concise review. Revista de gastroenterologia de Mexico, 78(1), 35-44. (Read full publication)
    4. Chandna S, Rodriguez Zarate E, Gallegos-Orozco J (2021). Management of decompensated cirrhosis and associated syndromes. The Surgical clinics of North America, 102, 117-137.
    5. Gallegos-Orozco JF, Charlton M (2016). Alcoholic Liver Disease and Liver Transplantation. Clinics in liver disease, 20(3), 521-34. (Read full publication)
    6. Gallegos-Orozco JF, Charlton M (2017). Predictors of cardiovascular events after liver transplantation. Clinics in liver disease, 21(2), 367-379.
    7. Chandna S, Zarate ER, Gallegos-Orozco J (2022). Management of Decompensated Cirrhosis and Associated Syndromes. The Surgical clinics of North America, 102(1), 117-137. (Read full publication)
    8. Izzy M, Fortune BE, Serper M, Bhave N, deLemos A, Gallegos-Orozco JF, Guerrero-Miranda C, Hall S, Harinstein ME, Karas MG, Kriss M, Lim N, Palardy M, Sawinski D, Schonfeld E, Seetharam A, Sharma P, Tallaj J, Dadhania DM, VanWagner L (2022). Management of Cardiac Diseases in Liver Transplant Recipients: Comprehensive Review and Multidisciplinary Practice-Based Recommendations. American journal of transplantation, 22(12), 2740-2758. (Read full publication)
    9. Izzy M, Fortune BE, Serper M, Bhave N, deLemos A, Gallegos-Orozco JF, Guerrero-Miranda C, Hall S, Harinstein ME, Karas MG, Kriss M, Lim N, Palardy M, Sawinski D, Schonfeld E, Seetharam A, Sharma P, Tallaj J, Dadhania DM, VanWagner L (2022). Management of cardiac diseases in liver transplant recipients: Comprehensive review and multidisciplinary practice-based recommendations. American journal of transplantation, 22(12), 2740-2758. (Read full publication)

    Book Chapter

    1. Unzueta A, Gallegos-Orozco J (2012). Esteatohepatitis no alcohólica, ¿Cuál es el mejor método diagnóstico?. 265-74.
    2. Costilla VC, Gallegos-Orozco J (2012). Terapias biológicas en el hepatocarcinoma. 373-88.
    3. Gallegos-Orozco JF, Vargas H (2012). Drug-Induced, Granulomatous, and Other Inflammatory Hepatic Diseases. 389-98.
    4. Hatch J, Gallegos-Orozco J (2013). Preoperative evaluation of patients with cirrhosis. 107-12.
    5. Porres-Aguilar M, Gallegos-Orozco J (2013). Pulmonary complications in liver cirrhosis. 153-7.
    6. Gallegos-Orozco JF, Campsen (2015). Liver transplant-related malignancies. 1191-1209.
    7. Doycheva I, Gallegos-Orozco J (2016). Acute viral hepatitis: hepatitis A, hepatitis E and other viruses. 465-72.
    8. Pham T, Gallegos-Orozco J (2014). New treatments for chronic hepatitis C.
    9. Gallegos-Orozco J (2015). Tratamiento actual del enfermo con hepatitis crónica por hepatitis C: un ejemplo de medicina traslacional [Current treatment of chronic hepatitis C: an example of translational medicine]. 43-49.
    10. Unzueta Santos A., Gallegos-Orozco J (2016). Fibrosis hepática: nuevas alternativas terapéuticas. [Liver fibrosis: new therapeutic options]. 13-18.
    11. García Sáenz de Sicilia M, Gallegos-Orozco J (2016). Tratamiento actual de la hepatitis crónica por virus de la hepatitis C [Current treatment of chronic hepatitis C]. 119-124.
    12. Unzueta A, Gallegos-Orozco J (2017). Factores de riesgo en tumores hepaticos [Risk factors for liver tumors]. 121-125.
    13. Gallegos-Orozco J (2023). Hepatitis por inhibidores del punto de control inmunitario [Immune checkpoint inhibitor hepatitis]. 83-88.
    14. Aguilar MT, Chandna S, Gallegos-Orozco J (2023). Primary Sclerosing Cholangitis. 95-102.

    Case Report

    1. Gallegos-Orozco JF, Paskvan-Gawryletz CD, Gurudu SR, Orenstein (2012). Successful colonoscopic fecal transplant for severe acute Clostridium difficile pseudomembranous colitis. Revista de gastroenterologia de Mexico, 77(1), 40-2. (Read full publication)
    2. Werner KT, Gallegos-Orozco J (2012). Multiple hepatic abscesses secondary to chicken bone penetration of the colon: a case report. Revista de gastroenterologia de Mexico, 77(1), 43-6. (Read full publication)
    3. Gallegos-Orozco JF, Gurudu SR, Orenstein (2012). First successful colonoscopic fecal transplant for severe acute Clostridium difficile pseudomembranous colitis. Revista de gastroenterologia de Mexico,
    4. Chaly T, Campsen J, O'Hara R, Hardman R, Gallegos-Orozco JF, Thiesset H, Kim R (2017). Mucocele mimicking a gallbladder in a transplanted liver: A case report and review of the literature. World journal of transplantation, 7(6), 359-363. (Read full publication)
    5. Horner BJ, Craig R, Harris ES, Kovacsovics T, Gallegos-Orozco JF (2017). Acute liver failure secondary to AL amyloidosis. Clinical medical reviews and case reports, 4(2), 157.

    Editorial

    1. Gallegos-Orozco J (2019). The Growing Challenge of Advanced Liver Disease Due to Alcohol Use in the United States. The American journal of gastroenterology, 114(11), 1712-1713. (Read full publication)
    2. Gallegos-Orozco JF, Charlton M (2015). Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful?. Liver international, 35(1), 9-11. (Read full publication)

    Abstract

    1. Abduljawad B, Hatch J, Lynch KM, Stevens K, Thomason IR, Box TD, Gallegos-Orozco JF (2016). Real world experience with interferon-free direct acting antivirals in the treatment of patients with chronic hepatitis C. Accepted for presentation during DDW in San Diego, California, USA, May 2016. Gastroenterology, 150(Supplement 1), S1104.
    2. Chervenak AE, Bashar A, Byrne TJ, Carey EJ, Rakela J, Hartel LA, Gallegos-Orozco JF, Sapola AM, Vargas HE (2012). Treatment of HCV in the DAA era: the impact of a multidisciplinary team. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases in Boston, MA. Hepatology (Baltimore, Md.), 56(Suppl), 228A.
    3. Gallegos-Orozco JF, Chervenak AE, Carey EJ, Bashar A, Byrne TJ, Hartel LA, Rakela J, Vargas H (2012). Liver transplant center focused experience with peginterferon alfa-2ª, ribavirin and telaprevir therapy in patients with genotype 1 hepatitis C cirrhosis. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases in Boston, MA,. Hepatology (Baltimore, Md.), 56(Suppl), 218A-219A.
    4. Haseeb A, Gallegos-Orozco J (2014). Hepatic encephalopathy, a preventable readmission: implementation of quality indicators at a tertiary care center. 65th Annual Meeting of the American Association for the Study of Liver Diseases in Boston, MA. Hepatology (Baltimore, Md.), (Supp 60), 397A.
    5. Unzueta A, Moreira RK, De Petris G, Smith ML, Chang Y-H H, Cheng M-R, Eyshou A, Gallegos-Orozco JF, Aqel B, Vargas H (2014). Validation of the hepatitis aggressiveness score in a liver transplant population with recurrent hepatitis C. 65th Annual Meeting of the American Association for the Study of Liver Diseases in Boston, MA. Hepatology (Baltimore, Md.), (Supp 60), 535A.
    6. Gallegos-Orozco JF, Silva AM, Chang Y-H, Batheja MJ, Hansen KL, Lam-Himlin D, De Petris G, Carey EJ, Aqel BA, Byrne TJ, Douglas DD, Mulligan DC, Rakela J, Silva A, Vargas H (2012). Magnetic resonance elastography (MRE) can discriminate normal vs. abnormal liver biopsy in candidates for live liver donation. Presented at the International Liver Congress in Barcelona, Spain. Journal of hepatology, (56), S96.
    7. Gallegos-Orozco JF, Silva AM, Chang Y-H, Batheja MJ, Hansen KL, Lam-Himlin D, De Petris G, Carey EJ, Aqel BA, Byrne TJ, Douglas DD, Mulligan DC, Silva A, Vargas H (2012). Magnetic resonance elastography (MRE) can discriminate normal vs. abnormal liver biopsy in candidates for live liver donation. Young Investigator Award Winner. Presented at the International Liver Transplantation Society 17th Annual International Congress. San Francisco, CA. Liver transplantation, 18(Suppl 1), S111.
    8. Campsen J, Kim R, Thiesset H, Chaly T, Shihab F, Ahmed F, Gallegos-Orozco JF (2016). Expanding the donor pool using HCV+ kidneys to cure HCV and end-stage renal disease. American journal of transplantation, 16(S1), 44-45.
    9. Parbhu SK, Haseeb A, Gallegos-Orozco JF (2015). Ursodeoxycholic acid (UDCA) therapy in acute cytomegalovirus (CMV) hepatitis associated cholestasis. Accepted for presentation at the 80th Annual Meeting of the American College of Gastroenteorlogy in Honolulu, Hawaii.

  • News & Podcasts

    Podcasts